Compare Philip Morris International Inc. (PM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Philip Morris International Inc. vs TransMedics Group Inc — how do they compare? Philip Morris International Inc. trades at $185.71 (market cap $287.92B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: Philip Morris International Inc. is far larger — about 94.1× TransMedics Group Inc's market cap, and Philip Morris International Inc. pays a 3.18% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| PM | TMDX | |
|---|---|---|
Market Cap | $287.92B | $3.06B |
Sector | Consumer Staples | Technology |
52-Week High | $200.17 | $150.42 |
52-Week Low | $144.33 | $61.99 |
Enterprise Value | $331.04B | $3.46B |
Dividend Yield | 3.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Philip Morris International (PM) trades at $185.71, up 1.74% with a bearish technical signal. Recent earnings show beats in Q1 and Q2 2026, but the company cut its 2026 profit forecast due to a $500 million impairment and cost pressures. Fundamentals remain strong with a 25.56% net margin and $11.35B net income in 2025, though high debt and illicit market growth in Europe pose risks. Analyst consensus is bullish with a $211.17 price target.
The stock offers a solid dividend and brand strength via IQOS, but faces headwinds from currency swings, energy costs, and regulatory challenges. Upside depends on execution amid margin pressure, with the current price near the low end of analyst targets suggesting cautious optimism for long-term investors.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
